Navigation Links
AtheroNova Initiates Phase 1 Clinical Trial of AHRO-001, a Potential Treatment for Atherosclerosis
Date:6/25/2013

aque and is now starting human studies in pursuit of these same successful results.

About AtheroNova

AtheroNova Inc. is a biotechnology company focused on the discovery, research, development and licensing of novel compounds to safely reduce or regress atherosclerotic plaque deposits and improve lipid profiles in humans. In addition to its lead compound AHRO-001, AtheroNova plans to develop multiple applications for its patented and patents-pending therapies in market sectors that include: Cardiovascular Disease, Stroke, Peripheral Artery Disease, Dementia and Alzheimer's and Erectile Dysfunction, all of which have been linked to atherosclerosis. Atherosclerosis and its related pharmaceutical expenses for these indications cost consumers more than $41 billion annually in the United States alone. For more information, please visit www.AtheroNova.com.

About OOO CardioNova

OOO CardioNova is an operational company in the Russian Federation founded by Maxwell Biotech Group to conduct clinical trials of AHRO-001, seek its approval, and then commercialize it in the territories covered by the license agreement.

About Maxwell Biotech Group

Maxwell Biotech Group is a development partner and financial resource for biotechnology companies. Maxwell provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Maxwell's unique business model can add value to its partners' pipelines and provide a commercialization path to one of the most lucrative emerging markets. Maxwell relies on an experienced international team of managers and financial and industry experts, with offices in Moscow, Boston and San Diego
'/>"/>

SOURCE AtheroNova Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. AtheroNova Announces Milestone Filing of IND in Russian Federation
2. AtheroNova Receives Notice of Allowance for Its US Patent Application 12/024,908
3. AtheroNova Signs Agreement for Development of Clinical Trial Supplies
4. Xenon Licenses Antisense Drug XEN701 From Isis and Initiates Preclinical Toxicology Studies
5. Spring Bank Pharmaceuticals Initiates a Phase I Clinical Trial for SB 9200 in HCV-infected Patients
6. AbbVie Initiates Phase 3 Study of Its Investigational Compound Atrasentan on Renal Outcomes in Patients with Diabetic Nephropathy
7. Soligenix Initiates Phase 1 Clinical Study with SGX203 for the Treatment of Pediatric Crohns Disease
8. Ambrx Initiates Collaboration with Bristol-Myers Squibb for Discovery, Development of Next-Generation Antibody Drug Conjugates
9. Acutus Medical, Inc. Initiates "First-In-Man" Clinical Study of Real-Time 3D Imaging Catheter with CT/MRI Quality
10. ISIS Pharmaceuticals Initiates a Clinical Study of ISIS-SMN Rx in Infants With Spinal Muscular Atrophy
11. Romark Laboratories Initiates Phase 3 Trial of New Influenza Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... Israele, February 27, 2015 ... sviluppo dell,innovativo sistema di monitoraggio dell,infarto congestizio (CHF ... sull,uomo-     ... di nuovo sistema per il monitoraggio cardiaco destinato ... annunciato oggi di aver concluso una raccolta di ...
(Date:2/27/2015)... Feb. 27, 2015  Boston Scientific Corporation (NYSE: ... Barclays 2015 Annual Healthcare Conference on March 10 in ... Dan Brennan , executive vice president and chief financial ... Relations, will participate in a 25-minute question and answer ... approximately 1:05 p.m. ET. Following a 5-minute break, a ...
(Date:2/27/2015)... Therapeutics, Inc. (NASDAQ: PTCT ) today announced ... fourth quarter and full year ended December 31, 2014. ... PTC. We are now a growing commercial-stage biopharma company, ... rare disease space," stated Stuart W. Peltz, Ph.D., Chief ... bring the first treatment for Duchenne muscular dystrophy to ...
Breaking Medicine Technology:Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Boston Scientific to Participate in the Barclays 2015 Annual Healthcare Conference 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 2PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 3PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 4PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 5PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 6PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 7PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 8PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 9PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 10PTC Therapeutics Reports Fourth Quarter and 2014 Full Year Financial Results and Provides Corporate Update 11
... U L URUI nc. (NYSE Amex: ... an abbreviated 510(k) application with the U.S. Food and Drug ... and mitigation of pain. The principal data supporting ... to Acquacel® Ag in skin graft donor sites. This amended ...
... 16, 2011 /PRNewswire-Asia/ -- ShangPharma Corporation (NYSE: ... "Company"), a leading China-based pharmaceutical and biotechnology ... that its wholly-owned contract research subsidiary, Shanghai ... agreement with Shenogen Pharma Group to develop ...
Cached Medicine Technology:ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 2ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 3ULURU Inc. Announces the Filing of a 510(k) Application to Expand Altrazeal®'s Label Claim 4Shanghai ChemPartner Announces Being Selected as Antibody Service Partner by Shenogen Pharma Group 2
(Date:2/28/2015)... The MCA Youth Empowerment Conference aims to ... and gears towards the goal for a better future ... talks in smaller groups will be held after the ... Leadership, Entrepreneurship, Healthcare, Social and Volunteerism, Women and Youth ... , Young adults aged between 18-30 years ...
(Date:2/28/2015)... In a recent episode of SCI TV ... Athlete Development Services and Consultancy talks with Joshua ... development and player engagement during and after their careers. ... face and how off-field activities are a critical component ... in athlete development issues while in graduate school coaching ...
(Date:2/28/2015)... (PRWEB) February 28, 2015 The Heart ... now a distributor of the machine. The Heart Fit ... their license, like a franchise model. The goal is ... and reverse heart disease. To buy External Counterpulsation ... Clinic can help individuals through this process and achieve ...
(Date:2/28/2015)... Mew and Company, a Vancouver corporate tax ... business consulting services in addition to a variety of ... succession planning. Company finances are a complicated matter that ... of this, complex Canadian tax laws can make it ... result, Mew and Company works to advise their clients ...
(Date:2/28/2015)... CA (PRWEB) February 28, 2015 A ... a promising new gene therapy procedure for the treatment ... blindness in patients. Authored by Dr. Robert ... and published in the Lancet Medical Journal on January ... from choroideremia, a rare genetic disorder that mostly affects ...
Breaking Medicine News(10 mins):Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 2Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 3Health News:My Mobile University Appointed Learning Partner for the Upcoming MCA’S First Youth Empowerment Conference Held in Malaysia on March 28, 2015 4Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2
... condition that causes clogging and narrowing of the arteries, ... walls. //Over a period of time, the plaque build–up ... arteries usually happens in adults. ,But, Canadian ... University in Hamilton, Ontario, have presented a report on ...
... that lead to dehydration can signal a future attack for ... American// College of Rheumatology Annual Scientific Meeting in Washington DC. ... causes severe pain and swelling of the joints. The attacks, ... few days, most often the big toe, can also generate ...
... by CANCER (a peer-reviewed journal of American Cancer ... breast cancer patients met clinically significant screening// criteria ... major depression and post-traumatic stress disorder (PTSD). The ... women admitted have been experiencing some level of ...
... World Diabetes Day is an opportune time to evaluate ... across the world coping with a galloping disease. Taking// ... - 'Diabetes Care for Everyone, especially the disadvantaged and ... campaign. ,The global initiative in diabetes ...
... A surge of new cases of HIV infection among injection ... of expenditure on HIV education next year according to a// ... million on HIV prevention which is only a 10th of ... director of AIDS and tuberculosis prevention at Taiwan's Center for ...
... based study conducted in Sweden points out that those children ... a result of allergy// to a substance called gluten chiefly ... more prone to developing Type I Diabetes mellitus which ... before the age of twenty. ,Lead author Dr. ...
Cached Medicine News:Health News:It's the Heat and the Humidity: How Each Worsens Gout Symptoms 2Health News:Breast Cancer Patients Suffer From Psychological Problems 2Health News:The Holy Grail of Diabetes Management 2Health News:The Holy Grail of Diabetes Management 3Health News:Surge of HIV Cases in Taiwan Prompts Doubling in Expenditure for HIV Prevention 2Health News:From the frying pan into the fire: Celiac disease and diabetes 2
SAS Strep A Test is a rapid visual test for the presumptive qualitative detection of Group A Streptococcal antigen from throat swab specimens. Group A streptococcus is the principal cause of respirat...
Poly stat Strep A is a lateral flow, one-step immunoassay for the rapid, qualitative detection of Group A Streptococcal antigen from throat swabs. The test is intended for use as an aid in the diagn...
HemataSTAT II has a manual reader. It uses both 0.5 and 1.1 ID capillary tubes., , Spins in just 60 seconds , Built-in reader with LCD display , Accuracy comparable to NCCLS reference method , Lid lo...
... S System offers unparalleld speed, providing ... minute requiring only 10 ul of ... provide more comprehensive patient care by ... The CoaguChek S System is easy-to-use, ...
Medicine Products: